Horizon Two Adaptive Platform Study in High Risk Newly Diagnosed Multiple Myeloma

NCT07053436 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

300

Enrollment

NETWORK

Sponsor class

Conditions

High Risk Newly Diagnosed Multiple Myeloma

Interventions

DRUG: Bispecific Monoclonal Antibody and Triplet Therapy
DRUG: Monoclonal Antibody with Stem Cell Transplant

Sponsor

Multiple Myeloma Research Consortium